Compared to the liraglutide non-NAFLD group, the inflammation marker sCD163 decreased significantly in the liraglutide NAFLD group (p < 0.01) but was unaltered in the placebo subgroups. The gene discussed is CD163; the disease is metabolic dysfunction-associated steatotic liver disease.